- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01913847
Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension
November 24, 2017 updated by: Hanmi Pharmaceutical Company Limited
Phase III Study to Evaluate Efficacy and Safety of HGP1207 in Patients With Pulmonary Hypertension Associated With Systolic Heart Failure
The purpose of this study is to investigate the safety and clinical efficacy of HGP1207 (Sildenafil) in subjects with pulmonary hypertension associated with systolic heart failure.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
144
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Bae
- Email: monobhy@hanmi.co.kr
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- 11 institutions including Hallym University Dongtan Sacred Heart Hospital
-
Contact:
- Ok
- Phone Number: 82-31-8086-2538
- Email: sokei@hanmail.net
-
Principal Investigator:
- Kyu Hyung Ryu, M.D. Ph.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with a diagnosis of chronic heart failure (NYHA Class II and III)
- LVEF ≤ 40%
- Elevated systolic PAP: ≥ 40 mmHg
- Patients must be treated with an ACE inhibitor, ARB, beta-blocker, aldosterone antagonist at a stable dose for at least 4 weeks prior to visit 1
Exclusion Criteria:
- Patients with pulmonary hypertension associated with chronic obstructive pulmonary disease, interstitial lung disease, chronic thromboembolism or unclear/multifactorial mechanisms
- Patients who have received Nitrates/NO donor or Cytochrome P450 3A4 inhibitors within 30 days prior to visit 1
- Patients who have received calcium channel blocker, endothelin receptor antagonist, prostacyclin analogues, phosphodiesterase 5 inhibitors within 90 days prior to visit 1
- History of hypersensitivity or allergy to sildenafil or any excipients of its formulation
- Patients with hypertension (sitSBP >170 mmHg or sitDBP>100 mmHg) or hypotension (sitSBP<90 mmHg or sitDBP<50 mmHg)
- Patients with other medical condition (i.e.,alcoholism, drug abuse) that may cause the patient to be non-compliant with the protocol, confound the data interpretation
- Pregnant females or those of child bearing potential who have not had a negative pregnancy test
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Oral placebo TID for 12 weeks
|
Experimental: Sildenafil
Sildenafil 20 mg
|
Oral sildenafil 20 mg TID for 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in 6-min-walk test distance
Time Frame: at 12 weeks
|
at 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in 6-min-walk test distance
Time Frame: at 6 weeks
|
at 6 weeks
|
Change from baseline in systolic pulmonary arterial pressure (PAP)
Time Frame: at 6 weeks and 12 weeks
|
at 6 weeks and 12 weeks
|
Change from baseline in [NT pro-BNP]
Time Frame: at 6 weeks and 12 weeks
|
at 6 weeks and 12 weeks
|
Improvement in NYHA functional class
Time Frame: at 6 weeks and 12 weeks
|
at 6 weeks and 12 weeks
|
Quality of life (QoL) assessed by EuroQoL(EQ-5D-3L) and EQ visual analogue scales (VAS)
Time Frame: at 6 weeks and 12 weeks
|
at 6 weeks and 12 weeks
|
Delaying time to first occurrence of either cardiovascular events
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Kyu Hyung Ryu, M.D. Ph.D., Hallym University Dongtan Sacred Heart Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2013
Primary Completion (Anticipated)
December 1, 2018
Study Completion (Anticipated)
December 1, 2018
Study Registration Dates
First Submitted
July 30, 2013
First Submitted That Met QC Criteria
July 31, 2013
First Posted (Estimate)
August 1, 2013
Study Record Updates
Last Update Posted (Actual)
November 27, 2017
Last Update Submitted That Met QC Criteria
November 24, 2017
Last Verified
November 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Heart Murmurs
- Hypertension
- Hypertension, Pulmonary
- Systolic Murmurs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Urological Agents
- Enzyme Inhibitors
- Phosphodiesterase Inhibitors
- Phosphodiesterase 5 Inhibitors
- Sildenafil Citrate
Other Study ID Numbers
- HM-SIL-301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Hypertension
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Heidelberg UniversityMerck Sharp & Dohme LLCRecruitingChronic Thromboembolic Pulmonary Hypertension | Primary Pulmonary Arterial HypertensionGermany
-
University of South FloridaWithdrawnPulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Idiopathic Pulmonary Arterial Hypertension | Primary Pulmonary HypertensionUnited States
-
BayerCompletedPrimary HypertensionChina
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
University of Kansas Medical CenterRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Hypertension Due to Left Heart Disease | Pulmonary Hypertension, Primary, 4 | Pulmonary Hypertension, Primary, 2 | Pulmonary Hypertension, Primary, 3 | Pulmonary Hypertension, Primary and other conditionsUnited States
-
Papworth Hospital NHS Foundation TrustMerck Sharp & Dohme LLCCompleted
-
University of ZurichCompletedPulmonary Hypertension | Pulmonary Artery Hypertension | Chronic Thromboembolic Pulmonary HypertensionSwitzerland
-
National Taiwan University HospitalUnknownPulmonary HypertensionTaiwan
Clinical Trials on Sildenafil
-
University of PennsylvaniaWalter Reed National Military Medical CenterRecruiting
-
Rambam Health Care CampusUnknown
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI); PfizerCompleted
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedErectile DysfunctionSingapore
-
Northwestern UniversityCompletedHand Foot Skin ReactionUnited States
-
The Cleveland ClinicCompletedPulmonary Hypertension | Diffuse Parenchymal Lung DiseaseUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Rigshospitalet, DenmarkGlostrup University Hospital, CopenhagenCompletedBecker Muscular DystrophyDenmark
-
iX Biopharma Ltd.Linear Clinical ResearchCompletedErectile DysfunctionAustralia
-
N4 Pharma UK Ltd.BDD Pharma LtdCompleted